Live Breaking News & Updates on Volker Knappertz

Stay updated with breaking news from Volker knappertz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF and APRIL

Upon FDA clearance of the IND, AUR 200 will be studied in a. ....

United States , Volker Knappertz , Research Development , Drug Administration , American College Of Rheumatology Convergence , Aurinia Pharmaceuticals , Aurinia Pharmaceuticals Inc , Investigational New Drug , B Cell Activating Factor , Proliferation Inducing Ligand , Executive Vice President , American College , Rheumatology Convergence , Increased Potency , Accessed December ,

Aurinia Pharmaceuticals (AUPH) Submits IND Application to the FDA for AUR 200

Aurinia Pharmaceuticals (AUPH) Submits IND Application to the FDA for AUR 200
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Volker Knappertz , American College Of Rheumatology Convergence , Aurinia Pharmaceuticals Inc , Research Development , Drug Administration , Aurinia Pharmaceuticals , Investigational New Drug , B Cell Activating Factor , Proliferation Inducing Ligand , Executive Vice President , American College , Rheumatology Convergence ,

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Dede Sheel , Volker Knappertz , Aurinia Pharmaceuticals Inc , Aurinia Pharmaceuticals , Company Compensation Committee , Compensation Committee , Executive Vice President , Scott Habig , Chief Commercial Officer , Nasdaq Listing Rule , British Columbia , President Investor Relations ,

Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and P

Volker Knappertz, MD, as Executive Vice President, Research and Development, to lead the consolidated R&D function and to further enhance and advance the Aurinia pipelineScott Habig, as Chief Commercial Officer, to lead and enhance Aurinia’s commercial capabilities, replacing Max Colao, who led the formation of the. ....

United States , United Kingdom , Robertb Huizinga , Volker Knappertz , Peter Greenleaf , Dede Sheel , Neil Solomons , Scott Habig , Max Colao , Dana Lynch , Neurology At Yale University , Ucb Inc , Sales At Human Genome Sciences , Gw Pharmaceuticals , Centocor Inc , Heinrich Heine University , Anacor Pharmaceuticals , Global Clinical Development At Teva Pharmaceuticals , Cologne University , Stern School Of Business , Aurinia Pharmaceuticals Inc , Health Science , Myovant Sciences , Deutsche Bank , Corporate Communications , University Of Pennsylvania ,

Why Aurinia Pharmaceuticals Stock Is In Retreat Today

Investors are none too pleased with the company's recent slew of hires. ....

Dede Sheel , Volker Knappertz , Scott Habig , Aurinia Pharmaceuticals ,